Document Detail

Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
MedLine Citation:
PMID:  23442756     Owner:  NLM     Status:  Publisher    
STUDY QUESTION: Will sequential administration of highly purified (hp)-HMG after corifollitropin alfa in a GnRH antagonist protocol benefit women with poor ovarian response according to the Bologna criteria? SUMMARY ANSWER: Corifollitropin alfa followed by hp-HMG in a GnRH antagonist protocol results in very promising pregnancy rates, albeit only in young (<40 years old) poor ovarian responders fulfilling the Bologna criteria. WHAT IS KNOWN ALREADY: Poor ovarian responders fulfilling the Bologna criteria have a very poor prognosis in terms of successful IVF outcome. Although a recent study demonstrated low pregnancy rates in this group of patients after treatment with corifollitropin alfa followed by recombinant FSH in a GnRH antagonist protocol, previous studies showed that the addition of LH activity in 36- to 39-year-old women significantly increases implantation rates. STUDY DESIGN, SIZE, DURATION: In this retrospective pilot study, we included poor ovarian responders fulfilling the Bologna criteria treated with a completely novel protocol, with corifollitropin alfa followed by hp-HMG in a GnRH antagonist setting. Overall, 51 patients were treated within a period of 1 year (August 2011-August 2012). PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients received 150 μg corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on Day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU hp-HMG was administered until the day of ovulation triggering. The primary outcome was ongoing pregnancy rate per patient. MAIN RESULTS AND THE ROLE OF CHANCE: Among 47 eligible women, 29 patients were <40 years old and 18 patients were ≥40 years old. No differences were observed in endocrine profile, number of cycles with oocyte retrieval (66 versus 67%) and cycles with embryo transfer (62 versus 61%) in women <40 versus ≥40 years old, respectively. However, 8 of the 29 women <40 years old had an ongoing pregnancy (28%) compared with 0 of 18 patients who were ≥40 years of age (P = 0.017). LIMITATIONS, REASONS FOR CAUTION: Owing to the specific retrospective study design, bias cannot be ruled out and these results should not be extrapolated to other treatment protocols for poor ovarian responders. Therefore, caution should be taken when interpreting the results. WIDER IMPLICATIONS OF THE FINDINGS: The promising results from this pilot study of corifollitropin alfa followed by hp-HMG stimulation indicate a potential beneficial effect in young poor ovarian responders fulfilling the Bologna criteria. The data provide the rationale for performing a randomized controlled trial to determine if there is sound evidence for a clinical introduction of this protocol. STUDY FUNDING/COMPETING INTEREST(S): No conflicts of interest to declare. No specific funding was received for this study.
N P Polyzos; M De Vos; R Corona; V Vloeberghs; C Ortega-Hrepich; D Stoop; H Tournaye
Related Documents :
7931586 - Intracranial dural arteriovenous fistulae: angiographic predictors of intracranial hemo...
17048766 - Technical description, phantom accuracy, and clinical feasibility for fiducial-free fra...
21063336 - Predictors of outcome for non-traumatic intracerebral hemorrhage.
12459366 - Cognitive function in patients with cerebral arteriovenous malformations after radiosur...
22955406 - Structural and biomechanical characteristics after early mobilization in an achilles te...
23147406 - Bipolar versus monopolar transurethral resection of the prostate: results of a comparat...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-26
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  -     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II...
Next Document:  International Committee for Monitoring Assisted Reproductive Technologies (ICMART) world report: ass...